Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821765 | 0.88 | HDAC1 (0.58) | HDAC1KCNH2 | |
| SCHEMBL4899379 | 0.83 | HDAC1 (0.69) | HDAC1KCNH2BRD4JAK1 | |
| SCHEMBL4891759 | 0.83 | HDAC1 (0.96) | HDAC1KCNH2 | |
| SCHEMBL4899695 | 0.82 | HDAC1 (0.75) | HDAC1KCNH2BRD4JAK1 | |
| SCHEMBL4898273 | 0.81 | HDAC1 (1.00) | HDAC1KCNH2 | |
| SCHEMBL4898587 | 0.78 | HDAC1 (0.86) | HDAC1KCNH2 | |
| SCHEMBL4890641 | 0.77 | HDAC1 (0.67) | HDAC1KCNH2 | |
| SCHEMBL4893535 | 0.77 | HDAC1 (0.81) | HDAC1KCNH2BRD4JAK1 | |
| SCHEMBL4887589 | 0.76 | HDAC1 (0.47) | HDAC1 | |
| SCHEMBL4896659 | 0.76 | HDAC1 (1.00) | HDAC1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | claimed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | claimed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885KCNH2 1230/4885BRD4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.